BRCA1 and prostate cancer: The exact role of taxane based chemotherapy for the treatment of BRCA1/2 mutated prostate cancer patients has therefore to be further elucidated but our data suggest that patients with known BRCA1/2 mutation should be carefully monitored for PSA response when receiving a taxane based chemotherapy.